U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164976) titled 'Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer' on Aug. 23.
Brief Summary: This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic or recurrent breast cancer. The trial aims to evaluate the efficacy (specifically, overall response rate) and safety of this combination in the Japanese patient population. Nagoya City University is the sponsor of this trial, with funding provided by Novartis Pharma K.K..
Study Design and Endpoints: The tri...